Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia

NCT00510939 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
72
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Bologna

Collaborators